Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid

Marsot, Amélie; Ménard, Amélie; Dupouey, Julien; Muziotti, C.; Guilhaumou, Romain; Blin, Olivier

doi:10.1111/bcp.13178

Cited by 14 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To summarize, as RIF is a sensitive substrate of OATP1B1 and FA is an inhibitor of this transporter, we assume that FA could reduce the hepatic uptake and presystemic clearance of RIF, resulting in increased bioavailability and plasma concentrations, as found by Marsot et al . As FA also inhibits BCRP, a reduction in RIF biliary excretion may also participate in the interaction, but this remains to be proven.…”

Section: Tables Of Linksmentioning

confidence: 76%

Mechanisms of drug–drug interaction between rifampicin and fusidic acid

Bel

Bourguignon

Tod

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Tables Of Linksmentioning

confidence: 76%

Mechanisms of drug–drug interaction between rifampicin and fusidic acid

Bel

Bourguignon

Tod

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…We have previously developed a rifampicin population PK model in adult patients with OAI. 11 18 R version 3.5.1 software (www.r-project.org) was used for graphical displays. As in our previous publication, 11 an initial analysis was performed to identify the base model (parameterized by clearance and volume of distribution) that best described the data.…”

Section: Population Pk Analysismentioning

confidence: 99%

“…11 18 R version 3.5.1 software (www.r-project.org) was used for graphical displays. As in our previous publication, 11 an initial analysis was performed to identify the base model (parameterized by clearance and volume of distribution) that best described the data. Models incorporating transit compartments were fitted to the data during the initial stage of model building.…”

Section: Population Pk Analysismentioning

confidence: 99%

“…As described in our previous study, the influences of each covariate on the PK parameters were then tested. 11 The internal model evaluation included the inspection of goodness-of-fit plots. Estimated parameters were checked for plausibility and precision.…”

Section: Population Pk Analysismentioning

confidence: 99%

“…5 Other studies report successful treatment with a dose of 20 mg/kg/d, without specifying the schedule, 1,9 or recommend different dose, such as 900 mg once daily. 10 In our institute, therapeutic schedule of rifampicin consist in a dosage of 900 mg daily, divided in 3 intakes of 300 mg. 11 Consequently, rifampicin dose is not consensual throughout the literature and guidelines, ranging from 600 to 1200 mg daily (in 1, 2 or 3 divided doses). 4,5,12 Moreover, an optimal dosing regimens and schedule appropriate for pharmacokinetic/pharmacodynamic (PK/PD) targets have been described as an important element in optimizing patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections

Marsot

Ménard

Dupouey

et al. 2020

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

We aimed to evaluate the actual rifampicin dosing regimens using a population pharmacokinetic model of rifampicin in patients with osteoarticular infections. A Monte Carlo simulation study was performed to simulate steady-state plasma concentrations for 1000 randomly sampled subjects using a total daily dose between 600 and 1200 mg (600 and 900 mg once daily, 450 and 600 mg twice daily, or 300 mg 3 times daily). When rifampicin was administered with fusidic acid, the pharmacokinetic/pharmacodynamic (PK/PD) target (area under the curve/minimum inhibitory concentration ≥952) was achieved with all tested dosing regimen, except 600 mg once daily for Staphylococcus epidermidis infections. Without coadministration of fusidic acid, none of tested dosing regimens achieved this PK/PD target. Most recommended drug-dosing regimens allow attaining the fixed area under the curve/minimum inhibitory concentration target for Staphylococcus aureus and coagulase-negative staphylococcal osteoarticular infections. In future studies, PK/PD target for osteoarticular infections in human should also be confirmed.

show abstract

Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model

Thirion

Pasche

Matouk

et al. 2020

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Background In patients with cystic fibrosis (CF), amikacin is the alternative for the treatment of acute pulmonary exacerbations associated with pathogens resistant to tobramycin. Population pharmacokinetic (PK) models of amikacin in adult patients with CF have been previously published. However, current dosing recommendations remain disputed (Illamola et al. Clin Pharmacokinet. 2018;57(10):1217‐1228). We perform here the first external evaluation of a published amikacin adult CF population PK model and propose a dosing nomogram for initial dosing. Methods We retrospectively collected demographic, biological, and clinical data from the medical records of adult patients who had received intravenous amikacin. To assess the predictive performance of this model we applied visual comparison of predictions to observations, calculation of bias and inaccuracy, and simulation‐based diagnostics. Monte Carlo simulations from the evaluated model were used to compare maximum concentration/minimum inhibitory concentration achieved with different dosing regimens. Results A total of 91 concentrations from 19 adult patients with CF were collected for external evaluation. The model predicted amikacin concentrations with reasonable bias (7.2% [95% confidence interval, CI: −0.7% to 15.0%]) and inaccuracy (18.2% [95% CI: 12.0%‐24.4%]). Our simulations with this model suggest that administered amikacin doses must be adjusted to creatinine clearance and also adjusted to body weight (doses from 20 to 45 mg/kg/d). According to these simulations, we developed the Montreal amikacin nomogram to optimize amikacin dosing regimens in patients with CF. Conclusion In conclusion, we developed the first nomogram to optimize initial amikacin dosing regimens in patients with CF based on this external evaluation of a recently published amikacin population PK model.

show abstract

Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid

Cited by 14 publications

References 33 publications

Mechanisms of drug–drug interaction between rifampicin and fusidic acid

Mechanisms of drug–drug interaction between rifampicin and fusidic acid

Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections

Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model

Contact Info

Product

Resources

About